Skip to main content
SpringerLink
Log in

JAK2V617F allele burden in patients with myeloproliferative neoplasms

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Myeloproliferative neoplasms (MPNs) are clonal malignant diseases that represent a group of conditions including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The JAK2-V617F mutation is prevalent in almost all patients with MPNs and has become a valuable biomarker for diagnosis of MPNs. A different allele burden in these entities has long been noticed. The aim of our study was to assess the JAK2 allele burden in our JAK2V617F positive cases and its association with phenotype if any and to select a simple, sensitive assay for use in our clinical molecular diagnostic laboratory. Methodologies reported in this literature include amplification refractory mutation system–polymerase chain reaction (ARMS-PCR) and real-time quantitative polymerase chain reaction (RQ-PCR). We analyzed 174 cases by RQ-PCR for the quantification of JAK2V617F were initially screened by ARMS-PCR. We found that V617F allele burden in the entire population of patients was 73 % ranging from 0.97 to 95 %. The median V617F allele burden in PV patients was 40 %, MF was 95 %, and ET was 25 %. ARMS-PCR and RQ-PCR were proven to be sensitive since ARMS-PCR is a qualitative method; it can be used to screen JAK2V617F mutation and RQ-PCR was used to quantify the V617F cells. Our study suggests that JAK2V617F positivity is associated with MPNs, and its allele burden is an excellent diagnostic marker for disease subtypes, prognosis, disease phenotype and complication, and evolution. The data indicates that ARMS-PCR is simple and can be easily performed for the primary screening of JAK2V617F mutation, and RQ-PCR is sensitive enough to detect low mutant allele levels (>10 %), specific enough not to produce false positive results, and can be performed for the JAK2V617F allele burden quantification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Levine LR, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190–2197

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  2. Spivak JL (2004) The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 41:1–5

    Article  PubMed  CAS  Google Scholar 

  3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061

    Article  PubMed  CAS  Google Scholar 

  4. Jamieson CH, Gotlib J, Durocher JA (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 103:6224–6229

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. James C, Ugo V, LeCouedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434:1144–11486

    Article  PubMed  CAS  Google Scholar 

  6. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

    Article  PubMed  CAS  Google Scholar 

  7. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397

    Article  PubMed  CAS  Google Scholar 

  8. Steensma DP, Dewald GW, Lasho TL et al (2005) The JAK2V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207–1209

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953

    Article  PubMed  CAS  Google Scholar 

  10. Denys B, El Housni H, Nollet F, Verhasselt B, Philippe J (2010) A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide. J Mol Diagn 12(4):512–519

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Huijsmans CJ, Poodt J, Savelkoul PH, Hermans MH (2011) Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. J Mol Diagn 13(5):558–564

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7):1299–1307

    Article  PubMed  Google Scholar 

  13. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14–22

    Article  PubMed  CAS  Google Scholar 

  14. Steensma DP (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8(4):397–411, quiz 526

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  15. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B et al (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94:38–45

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Dino V, Enrico C, Matteis G, Franchini M, Elisabetta B, Benati M, Pietro Soler G, Achille A, Giulia Q, Giovanni Pizzolo (2009) Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus 7:204–209. doi:10.2450/2009.0070-08

    Google Scholar 

  17. Milena C, Lisa W, Robert Hawley C, Richard Zarbo J, Dhananjay C (2009) Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory. Evaluation of screening and quantitation methods. Am J Clin Pathol 132:713–721

    Article  CAS  Google Scholar 

  18. Buors C, Douet N, Morel F, Lecucq L, Cassinat B, Ugo V (2012) Blood Cancer J 2:e66. doi:10.1038/bcj.2012.11

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase A, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou E, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168

    Article  PubMed  CAS  Google Scholar 

  20. Tefferi A, Skoda R, Vardiman JW (2009) Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 6(11):627–637

    Article  PubMed  CAS  Google Scholar 

  21. Konstantou JK, Iliadi AC, Ioannou PC, Christopoulos TK, Anagnostopoulos NI, Kanavakis E et al (2010) Visual screening for JAK2V617F mutation by a disposable dipstick. Anal Bioanal Chem 397(5):1911–1916

    Article  PubMed  CAS  Google Scholar 

  22. Passamonti F, Rumi E et al (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94(1):7–10

    Article  PubMed Central  PubMed  Google Scholar 

  23. Veneri D, Capuzzo E et al (2009) Comparison of JAK2V617F assessment employing different molecular diagnostic techniques. Blood Transf 7:204–209

    Google Scholar 

  24. Korger N, Badbaran A, Holler E et al (2007) Monitoring of the JAK2V617F mutation by highly sensitive quantitative real-time PCR after allogenic stem cell transplantation in patients with myelofibrosis. Blood 109:1316–1321

    Article  CAS  Google Scholar 

  25. Jones AV, Silver RT, Waghorn K et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339–3341

    Article  PubMed  CAS  Google Scholar 

  26. Campbell PJ, Baxter EJ, Beer PA et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548–3555

    Article  PubMed  CAS  Google Scholar 

  27. Vannuchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952–1959

    Article  CAS  Google Scholar 

  28. Vannuchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846

    Article  CAS  Google Scholar 

  29. Walz C, Cross NPC, Van Etten RA et al (2008) Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22:1320–1334

    Article  PubMed Central  PubMed  Google Scholar 

  30. Morgan KJ, Gilliland DG (2008) A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 59:213–222

    Article  PubMed  CAS  Google Scholar 

  31. Chen Q, Lu P, Jones A et al (2007) Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. JMD 9:2

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait, P.O. BOX 24923-13110, Kuwait, Kuwait

    Salem H. Alshemmari

  2. Department of Medical Oncology, Medical Oncology and Stem Cell Transplant Centre, Al-Sabah Medical Area, Kuwait, Kuwait

    Reshmi Rajaan & Mohammad A. Al-Drees

  3. Faculty of Allied Health Sciences, Kuwait University, Kuwait, Kuwait

    Reem Ameen

  4. Dasman Diabetes Institute, Kuwait, Kuwait

    Marwa R. Almosailleakh

Authors
  1. Salem H. Alshemmari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reshmi Rajaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reem Ameen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad A. Al-Drees
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marwa R. Almosailleakh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salem H. Alshemmari.

Additional information

This work is funded by Kuwait Foundation for the Advancement of Sciences (KFAS grant number: 2008130204).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alshemmari, S.H., Rajaan, R., Ameen, R. et al. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann Hematol 93, 791–796 (2014). https://doi.org/10.1007/s00277-013-1988-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1988-6

Keywords

Search

Navigation